上海医药拟10.23亿元转让中美施贵宝30%股权

Core Viewpoint - Shanghai Pharmaceuticals plans to transfer 30% equity stake in its subsidiary, China Medical Shanghai Bristol-Myers Squibb Pharmaceutical Co., Ltd. (referred to as "China Medical Bristol-Myers Squibb"), through a public listing with a minimum transfer price of 1.023 billion yuan [1][2] Group 1: Transaction Details - The transfer price is based on the previous equity disposal plan by Bristol-Myers Squibb, which aimed to sell its 60% stake in China Medical Bristol-Myers Squibb for approximately 480 million USD, equating to 1.44 billion USD for Shanghai Pharmaceuticals' 30% stake [1] - The transaction will result in Shanghai Pharmaceuticals no longer holding any equity in China Medical Bristol-Myers Squibb if completed successfully [1] Group 2: Company Financials - China Medical Bristol-Myers Squibb, established in 1982, has a registered capital of 18.44 million USD and operates in the pharmaceutical manufacturing sector [2] - For the fiscal year 2024 and the first three quarters of 2025, the company reported revenues of 1.795 billion yuan and 1.096 billion yuan, with net profits of 248 million yuan and 87.11 million yuan, respectively [2] - As of September 30, 2025, the total assets of China Medical Bristol-Myers Squibb amounted to 1.262 billion yuan, with net assets of 797 million yuan [2] Group 3: Strategic Implications - The transaction is expected to maximize asset value and protect the interests of all shareholders, particularly minority shareholders [1] - Shanghai Pharmaceuticals asserts that this transaction will not significantly impact its normal operations and financial status, while also optimizing its investment structure [2]